Anika Therapeutics (ANIK) 10-Q 22 May 20 2020 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2020	May 19, 2020
Document Information [Line Items]
Entity Registrant Name	Anika Therapeutics, Inc.
Entity Central Index Key	0000898437
Trading Symbol	anik
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		14,202,273
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Mar. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Amendment Flag	false
Title of 12(b) Security	Common Stock, par value $0.01 per share

Consolidated Balance Sheets (Cu

Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 65,833	$ 157,463
Investments	26,452	27,480
Accounts receivable, net of reserves of $935 and $962 at March 31, 2020 and December 31, 2019, respectively	28,101	23,079
Inventories, net	35,081	21,995
Prepaid expenses and other current assets	5,659	4,289
Total current assets	161,126	234,306
Property and equipment, net	54,232	50,783
Right-of-use assets	23,528	22,864
Other long-term assets	27,507	7,478
Intangible assets, net	98,718	7,585
Goodwill	33,802	7,694
Total assets	398,913	330,710
Current liabilities:
Accounts payable	9,906	3,832
Accrued expenses and other current liabilities	16,282	12,445
Total current liabilities	26,188	16,277
Other long-term liabilities	1,019	357
Contingent consideration	40,251
Deferred tax liability	16,030	4,331
Lease liabilities	21,731	21,367
Commitments and contingencies (Note 10)
Stockholders’ equity:
Preferred stock, $0.01 par value; 1,250 shares authorized, no shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively	0	0
Common stock, $0.01 par value; 90,000 shares authorized, 14,198 and 14,308 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively	142	143
Additional paid-in-capital	48,360	48,707
Accumulated other comprehensive loss	(6,027)	(5,898)
Retained earnings	251,219	245,426
Total stockholders’ equity	293,694	288,378
Total liabilities and stockholders’ equity	$ 398,913	$ 330,710

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) shares in Thousands, $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Accounts receivable, reserves	$ 935	$ 962
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	1,250	1,250
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	90,000	90,000
Common stock, shares issued (in shares)	14,198	14,308
Common stock, shares outstanding (in shares)	14,198	14,308

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenue	$ 35,397	$ 24,723
Operating expenses:
Cost of product revenue	14,200	7,311
Research & development	6,050	4,258
Selling, general & administrative	14,431	7,672
Goodwill impairment	18,144
Change in fair value of contingent consideration	(24,522)
Total operating expenses	28,303	19,241
Income from operations	7,094	5,482
Interest and other income, net	279	498
Income before income taxes	7,373	5,980
Provision for income taxes	1,580	1,473
Net income	$ 5,793	$ 4,507
Basic net income per share:
Net income (in dollars per share)	$ 0.41	$ 0.32
Basic weighted average common shares outstanding (in shares)	14,202	14,185
Diluted net income per share:
Net income (in dollars per share)	$ 0.40	$ 0.31
Diluted weighted average common shares outstanding (in shares)	14,353	14,314
Net income	$ 5,793	$ 4,507
Foreign currency translation adjustment	(129)	(315)
Comprehensive income	5,664	4,192
Product [Member]
Revenue	35,397	24,717
Service [Member]
Revenue		$ 6

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Restricted Stock Units (RSUs) [Member]Common Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance (in shares) at Dec. 31, 2018		14,210
Balance at Dec. 31, 2018		$ 142	$ 50,763	$ 218,233	$ (5,526)	$ 263,612
Issuance of common stock for equity awards (in shares)		7
Issuance of common stock for equity awards			5			5
Retirement of common stock for minimum tax withholdings (in shares)		(3)
Retirement of common stock for minimum tax withholdings			(124)			(124)
Net income				4,507		4,507
Other comprehensive income					(315)	(315)
Stock-based compensation expense			1,386			1,386
Balance (in shares) at Mar. 31, 2019		14,214
Balance at Mar. 31, 2019		$ 142	52,030	222,740	(5,841)	269,071
Balance (in shares) at Dec. 31, 2019		14,308
Balance at Dec. 31, 2019		$ 143	48,707	245,426	(5,898)	288,378
Issuance of common stock for equity awards (in shares)
Issuance of common stock for equity awards
Vesting of restricted stock units (in shares)	42
Forfeiture of restricted stock awards (in shares)		(9)
Forfeiture of restricted stock awards
Stock-based compensation expense			(207)			(207)
Retirement of common stock for minimum tax withholdings (in shares)		(4)
Retirement of common stock for minimum tax withholdings			(141)			(141)
Repurchase of common stock (in shares)		(139)
Repurchase of common stock		$ (1)	1
Net income				5,793		5,793
Other comprehensive income					(129)	(129)
Balance (in shares) at Mar. 31, 2020		14,198
Balance at Mar. 31, 2020		$ 142	$ 48,360	$ 251,219	$ (6,027)	$ 293,694

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash flows from operating activities:
Net income	$ 5,793	$ 4,507
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	2,761	1,477
Non-cash operating lease cost	340	297
Goodwill impairment	18,144
Change in fair value of contingent consideration	(24,522)
Loss on disposal of fixed assets		721
Loss on impairment of intangible asset	318	281
Stock-based compensation expense	(207)	1,386
Deferred income taxes	550	(124)
Provision (recovery) for doubtful accounts	(15)
Provision for inventory	831	381
Amortization of acquisition related inventory step-up	2,081
Amortization of premium and accretion of discount on investments and cash equivalents		(363)
Changes in operating assets and liabilities:
Accounts receivable	2,004	2,489
Inventories	(3,632)	(1,617)
Prepaid expenses, other current and long-term assets	(445)	(182)
Accounts payable	421	496
Operating lease liabilities	(310)	(269)
Accrued expenses, other current and long-term liabilities	(3,233)	(1,928)
Income taxes	166	910
Net cash provided by operating activities	1,045	8,462
Cash flows from investing activities:
Acquisition of Parcus Medical and Arthrosurface, net of cash acquired	(92,983)
Proceeds from maturities of investments	14,990	58,094
Purchases of investments	(13,787)	(58,981)
Purchases of property and equipment	(723)	(1,030)
Net cash used in investing activities	(92,503)	(1,917)
Cash flows from financing activities:
Cash paid for tax withheld on vested restricted stock awards	(141)	(124)
Proceeds from exercises of equity awards		5
Net cash used in financing activities	(141)	(119)
Exchange rate impact on cash	(31)	46
Increase (decrease) in cash and cash equivalents	(91,630)	6,472
Cash and cash equivalents at beginning of period	157,463	89,042
Cash and cash equivalents at end of period	65,833	95,514
Supplemental disclosure of cash flow information:
Right-of-use assets obtained in exchange for operating lease liabilities as of January 1, 2019	544	497
Non-cash Investing Activities:
Purchases of property and equipment included in accounts payable and accrued expenses	55	246
Consideration for acquisitions included in accounts payable and accrued expenses	2,085
Acquisition related contingent consideration	69,076
Accounting Standards Update 2016-02 [Member]
Supplemental disclosure of cash flow information:
Right-of-use assets obtained in exchange for operating lease liabilities as of January 1, 2019		$ 24,110

Note 1 - Nature of Business

Note 1 - Nature of Business	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Nature of Operations [Text Block]	1. Nature of Business Anika Therapeutics, Inc. (the “Company”) is a global, integrated joint preservation and regenerative therapies company based in Bedford, Massachusetts. The Company aims to be the global leader in its space with innovative technologies that exceed its customers’ expectations. The Company is committed to delivering therapies to improve the lives of patients across a continuum of care from joint pain management to orthopedic joint preservation and restoration. The Company has nearly thirty twenty two In early 2020, The Company is subject to risks common to companies in the biotechnology and medical device industries including, but not There are many uncertainties regarding the current pandemic of the novel coronavirus (“COVID- 19” 19 19 may may 19

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	2. Basis of Presentation The accompanying unaudited condensed consolidated financial statements and related notes have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and in accordance with accounting principles generally accepted in the United States (“US GAAP”). The financial statements include the accounts of Anika Therapeutics, Inc. and its subsidiaries. Inter-company transactions and balances have been eliminated. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with US GAAP have been condensed or omitted pursuant to SEC rules and regulations relating to interim financial statements. The December 31, 2019 The accompanying unaudited condensed consolidated financial statements and related notes should be read in conjunction with the Company’s annual financial statements filed with its Annual Report on Form 10 December 31, 2019. three March 31, 2020 not December 31, 2020. Segment Information Operating segments are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker is its interim President and Chief Executive Officer as of March 31, 2020. 280, Segment Reportin one Recent Accounting Adoptions In August 2018, No. 2018 15, Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350 40 No. 2015 05, Customers Accounting for Fees in a Cloud Computing Agreement 2018 15 350 40 2018 15 December 15, 2019. 2018 15 using the prospective method January 1, 2020. not In June 2016, No. 2016 13, Financial Instruments - Credit Losses 2016 13 December 15, 2019 2016 13 January 1, 2020. not not

Note 3 - Business Combinations

Note 3 - Business Combinations	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Business Combination Disclosure [Text Block]	3. Business Combinations Parcus Medical, LLC On January 24, 2020, ( January 4, 2020 ( The acquisition of Parcus Medical has been accounted for as a business combination under ASC 805. 805, fair value as of the acquisition date. no one three March 31, 2020, January 24, 2020 March 31, 2020. Consideration Transferred Pursuant to the Parcus Medical Merger Agreement, the Company acquired all outstanding $75.1 $32.8 $1.6 $40.7 The total preliminary purchase consideration is as follows: Cash consideration $ 32,794 Deferred consideration 1,642 Estimated fair value of contingent consideration 40,700 Estimated total purchase consideration $ 75,136 The deferred consideration is related to certain purchase price holdbacks which will be resolved within one March 31, 2020. may $60.0 2020 2022. Acquisition related costs are not $1.9 first 2020. Fair Value of Net Assets Acquired The preliminary estimate of fair value required the use of significant assumptions and estimates. Critical estimates included, but were not may hose estimates and assumptions are subject to change as the Company obtains additional information related to those estimates during the applicable measurement periods (up to one The preliminary allocation of purchase price to the identifiable assets acquired and liabilities assumed was based on preliminary estimates of fair value as of January 24, 2020, Recognized identifiable assets acquired and liabilities assumed: Cash and cash equivalents $ 196 Accounts receivable 2,029 Inventories 9,088 Prepaid expenses and other current assets 364 Property and equipment, net 1,099 Right-of-use assets 944 Intangible assets 44,000 Accounts payable, accrued expenses and other current liabilities (2,763 ) Other long-term liabilities (594 ) Lease liabilities (735 ) Net assets acquired 53,628 Excess purchase price over fair value of net assets acquired 21,508 Estimated total purchase consideration $ 75,136 The excess of the purchase price over the fair value of the net assets acquired was recorded as goodwill and assigned to the newly established reporting unit for Parcus Medical and Arthrosurface. The goodwill is attributable to the workforce of the business and the value of future technologies expected to arise after the acquisition. Goodwill will not January 24, 2020 Intangible assets acquired consist of: Developed Technology $ 41,100 Trade Name 1,800 Customer Relationships 1,100 Total Intangible Assets $ 44,000 The preliminary fair value of the developed technology intangible assets has been estimated using the multi-period excess earnings method, which is based on the principle that the value of an intangible asset is equal to the present value of the incremental after-tax cash flow attributable to the asset, after charges for other assets employed by the business. The preliminary fair value of the customer relationships has been estimated using the avoided costs/lost profits method, which is based on the principle that the value of an intangible asset is based on consideration of the total costs that would be avoided by having this asset in place. The preliminary fair value of the trade name has been estimated using the relief from royalty method of the income approach, which is based on the principle that the value of an intangible asset is equal to the present value of the after-tax royalty savings attributable to owning the intangible asset. Key estimates and assumptions used in these models are projected revenues and expenses related to the asset, estimated contributory asset charges, estimated costs to recreate the asset, and a risk-adjusted discount rate used to calculate the present value of the future expected cash inflows or cash outflows avoided from the asset. The final fair value determination of the identified intangible assets may $44.0 $41.1 15 $1.1 10 $1.8 5 Revenue, Net Loss and Pro Forma Presentation The Company recorded revenue from Parcus Medical of $2.6 $0.9 January 24, 2020 March 31, 2020. three March 31, 2020 2019 January 1, 2019 These pro forma adjustments include: (i) a net increase in amortization expense to record amortization expense for the $44.0 842, Leases not The following table presents unaudited supplemental pro forma information: For the Three Months Ended March 31, 2020 2019 Total revenue $ 32,103 $ 27,934 Net income 5,510 3,105 Earnings per share: Basic $ 0.39 $ 0.22 Diluted 0.38 0.22 Arthrosurface Incorporated On February 3, 2020, ( January 4, 2020 ( The acquisition of Arthrosurface has been accounted for as a business combination under ASC 805. 805, no one three March 31, 2020, February 3, 2020 March 31, 2020. Consideration Transferred Pursuant to the Arthrosurface Merger Agreement, the Company acquired all outstanding equity of Arthrosurface for estimated total purchase consideration of $90.3 $61.9 $28.4 The total preliminary purchase consideration is as follows: Cash consideration $ 61,909 Estimated fair value of contingent consideration 28,376 Estimated total purchase consideration $ 90,285 The cash consideration includes $0.4 March 31, 2020. may $40.0 2020 2021. 2020 2021 Acquisition related costs are not $2.2 Fair Value of Net Assets Acquired The preliminary estimate of fair value required the use of significant assumptions and estimates. Critical estimates included, but were not may one The preliminary allocation of purchase price to the identifiable assets acquired and liabilities assumed was based on preliminary estimates of fair value as of February 3, 2020, Recognized identifiable assets acquired and liabilities assumed: Cash and cash equivalents $ 1,072 Accounts receivable 5,368 Inventories 15,652 Prepaid expenses and other current assets 535 Property, plant and equipment 3,394 Other long-term assets 7,548 Intangible assets 48,900 Accounts payable, accrued expenses and other liabilities (3,929 ) Deferred tax liabilities (11,147 ) Net assets acquired 67,393 Excess purchase price over fair value of net assets acquired 22,892 Estimated total purchase consideration $ 90,285 The excess of the purchase price over the fair value of the net assets acquired was recorded as goodwill and assigned to the newly established reporting unit for Parcus Medical and Arthrosurface. The goodwill is attributable to the workforce of the business and the value of future technologies expected to arise after the acquisition. Goodwill will not not Intangible assets acquired consist of: Developed Technology $ 37,000 Trade Name 3,400 Customer Relationships 7,900 IPR&D 600 Total Intangible Assets $ 48,900 The preliminary fair value of the developed technology intangible assets has been estimated using the multi-period excess earnings method, which is based on the principle that the value of an intangible asset is equal to the present value of the incremental after-tax cash flow attributable to the asset, after charges for other assets employed by the business. The preliminary fair value of the customer relationships has been estimated using the avoided costs/lost profits method, which is based on the principle that the value of an intangible asset is based on consideration of the total costs that would be avoided by having this asset in place. The preliminary fair value of the trade name has been estimated using the relief from royalty method of the income approach, which is based on the principle that the value of an intangible asset is equal to the present value of the after-tax royalty savings attributable to owning the intangible asset. Key estimates and assumptions used in these models are projected revenues and expenses related to the asset, estimated contributory asset charges, estimated costs to recreate the asset, and a risk-adjusted discount rate used to calculate the present value of the future expected cash inflows or cash outflows avoided from the asset. The final fair value determination of the identified intangible assets may $48.9 $37.0 15 $7.9 10 $3.4 5 $0.6 Revenue, Net Loss and Pro Forma Presentation The Company recorded revenue from Arthrosurface of $4.2 $4.0 February 3, 2020 March 31, 2020. three March 31, 2020 2019 January 1, 2019 These pro forma adjustments include: (i) a net increase in amortization expense to record amortization expense for the $48.9 25%. may not The following table presents unaudited supplemental pro forma information (in thousands, except per share amounts): For the Three Months Ended March 31, 2020 2019 Total revenue $ 35,819 $ 31,494 Net income 1,601 22 Earnings per share: Basic $ 0.11 $ 0.00 Diluted 0.11 0.00

Note 4 - Fair Value Measurement

Note 4 - Fair Value Measurements	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Fair Value Disclosures [Text Block]	4. Fair Value Measurements The Company held U.S. treasury bills of $25.2 $1.3 March 31, 2020. $27.5 December 31, 2019. March 31, 2020 December 31, 2019, The Company’s investments are all classified within Levels 1 2 1 2 third not 3 The fair value hierarchy of the Company's cash equivalents, investments and liabilities at fair value was as follows: Fair Value Measurements at Reporting Date Using Quoted Prices in Active Markets Significant Other Significant for Identical Assets Observable Inputs Unobservable Inputs March 31, 2020 (Level 1) (Level 2) (Level 3) Amortized Cost Cash equivalents: Bank Certificates of Deposit $ 250 $ - $ 250 $ - $ 250 Money Market Funds 51,682 51,682 51,682 Total Cash equivalents $ 51,932 $ 51,682 $ 250 $ - $ 51,932 Investments: Bank Certificates of Deposit $ 1,250 $ - $ 1,250 $ - $ 1,250 U.S. Treasury Bills 25,202 25,202 - - 25,027 Total Investments $ 26,452 $ 25,202 $ 1,250 $ - $ 26,277 Other current and long-term liabilities: Contingent Consideration - Short Term $ 4,303 $ - $ - $ 4,303 $ 4,303 Contingent Consideration - Long Term 40,251 - - 40,251 40,251 Total Other current and long-term liabilities $ 44,554 $ - $ - $ 44,554 $ 44,554 Fair Value Measurements at Reporting Date Using Quoted Prices in Active Markets Significant Other Significant for Identical Assets Observable Inputs Unobservable Inputs December 31, 2019 (Level 1) (Level 2) (Level 3) Amortized Cost Cash equivalents: Money Market Funds $ 48,971 $ 48,971 $ - $ - $ 48,971 Investments: U.S. Treasury Bills $ 27,480 $ 27,480 $ - $ - $ 27,479 During fiscal years 2020 2019, no Contingent Consideration The following table provides a rollforward of the contingent consideration related to business acquisitions discussed in Note 3. March 31, 2020 Balance, beginning $ - Additions 69,076 Payments - Change in fair value (24,522 ) Balance, ending $ 44,554 Under the Parcus Medical and Arthrosurface merger agreements, there are earn-out milestones totaling $100 2020 2022. 2020 2022, 2020 2021. The unobservable inputs used in the fair value measurement of the Company’s contingent consideration are the probabilities of successful achievement, the weighted average cost of capital used for the Monte Carlo simulation, discount rate and the periods in which the milestones are expected to be achieved. The discount rate used for the net sales and regulatory earn-out milestones was 6.1% 60% 90% March 31, 2020. 11.5% 13.5% 14.5% 16.0% The fair value of contingent consideration is assessed on a quarterly basis. The $24.5 March 31, 2020 19

Note 5 - Inventories

Note 5 - Inventories	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Inventory Disclosure [Text Block]	5. Inventories Inventories consist of the following: March 31, December 31, 2020 2019 Raw materials $ 10,846 $ 12,058 Work-in-process 13,997 8,330 Finished goods 37,310 8,777 Total $ 62,153 $ 29,165 Inventories $ 35,081 $ 21,995 Other long-term assets 27,072 7,170 The increase in inventories for the three March 31, 2020 $24.7 January February 2020 3.

Note 6 - Intangible Assets

Note 6 - Intangible Assets	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	6. Intangible Assets Intangible assets as of March 31, 2020 December 31, 2019 Three months ended March 31, 2020 Gross Less: Accumulated Less: Less: Net Book Weighted Developed technology $ 93,953 $ (2,986 ) $ (318 ) $ (9,958 ) $ 80,691 15 In-process research & development 5,006 (1,296 ) - - 3,710 Indefinite Customer relationships 9,000 - - (99 ) 8,901 10 Distributor relationships 4,700 (415 ) - (4,285 ) - 5 Patents 1,000 (182 ) - (543 ) 275 16 Tradenames 5,200 - - (59 ) 5,141 5 Total $ 118,859 $ (4,879 ) $ (318 ) $ (14,944 ) $ 98,718 13 December 31, 2019 Gross Less: Accumulated Less: Less: Net Book Weighted Developed technology $ 17,100 $ (2,934 ) $ (389 ) $ (9,657 ) $ 4,120 15 In-process research & development 4,406 (1,234 ) – – 3,172 Indefinite Distributor relationships 4,700 (415 ) – (4,285 ) – 5 Patents 1,000 (176 ) – (531 ) 293 16 Elevess tradename 1,000 – – (1,000 ) – 9 Total $ 28,206 $ (4,759 ) $ (389 ) $ (15,473 ) $ 7,585 11 The aggregate amortization expense related to intangible assets was $1.3 $0.3 three March 31, 2020 2019, In the first 2020, 3, $92.9 March 31, 2020, not $0.3 three March 31, 2020. The Company assessed the recoverability of intangible and long-lived assets besides goodwill and concluded no March 31, 2020. not

Note 7 - Goodwill

Note 7 - Goodwill	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Goodwill Disclosure [Text Block]	7. Goodwill The Company assesses goodwill for impairment annually, or, under certain circumstances, more frequently, such as when events or changes in circumstances indicate there may may first not may not not not no As of December 31, 2019, 2019 Changes in the carrying value of goodwill for the three March 31, 2020 Three Months Ended March 31, 2020 Twelve Months Ended December 31, 2019 Balance, beginning $ 7,694 $ 7,851 Effect of foreign currency adjustments (148 ) (157 ) Acquisitions 44,400 - Impairment loss (18,144 ) - Balance, ending $ 33,802 $ 7,694 The increase in goodwill for the three March 31, 2020 January February 2020 3. two one The widespread economic volatility resulting from the COVID- 19 first 2020, 1 2 3 not not not March 31, 2020. U.S. government policy responses to the COVID- 19 March 31, 2020. This approach incorporates significant estimates and assumptions related to the forecasted results including revenues, expenses, the achievement of certain cost synergies, terminal growth rates and discount rates to estimate future cash flows. While assumptions utilized are subject to a high degree of judgment and complexity, the Company made reasonable assumptions to best estimate future cash flows under a high degree of economic uncertainty that existed as of March 31, 2020. The results of the interim impairment test indicated that the estimated fair value of the Parcus and Arthrosurface reporting unit was less than its carrying value. This is primarily due to decreases in near term revenue and related cash flows as a result of the temporary suspension of domestic elective procedures which directly impact the Parcus and Arthrosurface reporting unit. Consequently, a non-cash goodwill impairment charge was recorded as reflected in the table above. If the pandemic's economic impact is more severe, or if the economic recovery takes longer to materialize or does not

Note 8 - Leases

Note 8 - Leases	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Lessee, Operating Leases and Finance Leases [Text Block]	8. Leases The components of lease expense and other information are as follows: For the three months ended March 31, 2020 March 31, 2019 Amortization of ROU Assets $ 37 $ - Interest on finance lease liabilities 7 - Finance lease expense $ 44 $ - Operating lease expense 574 522 Short-term lease expense - 2 Variable lease expense 63 52 Total lease expense $ 681 $ 576 For the three months ended March 31, 2020 March 31, 2019 Weighted Average Remaining Lease Term (in years) Operating leases 16.4 17.6 Financing leases 3.8 - Weighted Average Discount Rate Operating leases 4.1 % 4.1 % Financing leases 5.1 % - Other information Operating cash flows from operating leases $ 544 $ 497 Operating cash flows from financing leases $ 51 $ - Future commitments due under these lease agreements as of March 31, 2020 Years ended December 31, Operating Leases Financing Leases Total 2020 (Remaining 9 months) $ 1,793 $ 204 $ 1,997 2021 2,304 174 2,478 2022 2,240 166 2,406 2023 2,123 160 2,283 2024 2,059 44 2,103 Thereafter 21,374 - 21,374 Present value adjustment (8,681 ) (66 ) (8,630 ) Present value of lease payments 23,212 682 23,894 Less current portion included in accrued expenses and other current liabilities (1,481 ) (214 ) (1,695 ) Total lease liabilities $ 21,731 $ 468 $ 22,199

Note 9 - Accrued Expenses

Note 9 - Accrued Expenses	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	9. Accrued Expenses Accrued expenses consist of the following: March 31, December 31, Compensation and related expenses $ 2,707 $ 5,830 Professional fees 4,908 3,850 Operating lease liability - current 1,481 1,141 Clinical trial costs 1,528 788 Acquisition related contingent consideration 4,303 - Financing lease liability - current 214 - Other 1,141 836 Total $ 16,282 $ 12,445

Note 10 - Commitments and Conti

Note 10 - Commitments and Contingencies	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	10. Commitments and Contingencies In certain of its contracts, the Company warrants to its customers that the products it manufactures conform to the product specifications as in effect at the time of delivery of the specific product. The Company may not third no March 31, 2020 December 31, 2019 no The Company is also involved from time-to-time in various legal proceedings arising in the normal course of business. Although the outcomes of these legal proceedings are inherently difficult to predict, the Company does not

Note 11 - Revenue

Note 11 - Revenue	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	11. Revenue The Company receives payments from its customers based on billing schedules established in each contract. Up-front payments and fees are recorded as deferred revenue upon receipt or when due and may March 31, 2020, $0.1 The Company has agreements with DePuy Synthes Mitek Sports Medicine, a division of DePuy Orthopaedics, Inc. (“Mitek”) that include the grant of certain licenses, performance of development services, and supply of product. Revenues from the agreements with Mitek represent 54% three March 31, 2020. may Product and Total Revenue Historically, the Company categorized our product offerings into four March 31, 2020, three Product revenue by product family was as follows: Three Months Ended March 31, 2020 2019 Joint Pain Management $ 25,483 $ 22,850 Orthopedic Joint Preservation and Restoration 7,896 163 Other 2,018 1,704 $ 35,397 $ 24,717 Total revenue by geographic location was as follows: Three Months Ended March 31, 2020 2019 Total Percentage of Total Percentage of Revenue Revenue Revenue Revenue Geographic Location: United States $ 26,306 74 % $ 20,089 81 % Europe 5,276 15 % 2,526 10 % Other 3,815 11 % 2,108 9 % Total $ 35,397 100 % $ 24,723 100 %

Note 12 - Equity Incentive Plan

Note 12 - Equity Incentive Plan	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	12. Equity Incentive Plan The Company estimates the fair value of stock options and stock appreciation rights (“SARs”) using the Black-Scholes valuation model. Fair value of restricted stock awards (“RSAs”) and restricted stock units (“RSUs”) is measured by the grant-date price of the Company’s shares. Fair value of performance restricted stock units (“PSUs”) is measured by the grant-date price of the Company’s shares with corresponding compensation cost recognized over the requisite service period. Compensation cost is recognized based on the estimated probabilities of achieving the performance goals. Changes to the probability assessment and the estimated shares expected to vest will result in adjustments to the related compensation cost that will be recorded in the period of the change. If the performance targets are not no The fair value of each stock option award during the three March 31, 2020 2019 Three Months Ended 2020 2019 Risk free interest rate 0.35% - 1.59% 2.44% - 2.54% Expected volatility 46.48% - 49.39% 44.34% - 44.41% Expected life (years) 4.0 3.5 Expected dividend yield 0.00% 0.00% The Company presents the expenses related to stock-based compensation awards in the same expense line items as cash compensation paid to each of its employees as follows: Three Months Ended 2020 2019 Cost of product revenue $ 146 $ 92 Research & development 196 177 Selling, general & administrative (549 ) 1,117 Total stock-based compensation expense $ (207 ) $ 1,386 On January 29, 2020, 2017 “2017 one $1.8 three March 31, 2020 The following table sets forth share information for stock-based compensation awards granted and exercised during the three March 31, 2020 2019: Three Months Ended 2020 2019 Grants: Stock options 210,775 104,292 RSUs 100,631 165,507 PSUs 57,400 114,500 Exercises: Stock options - 500 Forfeitures: Stock options 33,478 909 RSAs 8,574 3,333 RSUs 63,683 250 PSUs 63,000 - Expirations: Stock options 363 16,007 During the three March 31, 2020, three 40% 2020 2022 60% 2020 2022 $0.5 three March 31, 2020.

Note 13 - Earnings Per Share ("

Note 13 - Earnings Per Share ("EPS")	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Earnings Per Share [Text Block]	13. Earnings Per Share (“EPS”) Basic EPS is calculated by dividing net income by the weighted average number of shares outstanding during the period. Unvested restricted shares, although legally issued and outstanding, are not The following table provides share information used in the calculation of the Company's basic and diluted earnings per share (in thousands): Three Months Ended March 31, 2020 2019 Shares used in the calculation of basic earnings per share 14,202 14,185 Effect of dilutive securities: Stock options, RSAs, PSUs and RSUs 151 129 Diluted shares used in the calculation of earnings per share 14,353 14,314 Stock options of 0.6 1.0 three March 31, 2020 2019, not

Note 14 - Accelerated Share Rep

Note 14 - Accelerated Share Repurchases	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Accelerated Share Repurchases Disclosure [Text Block]	14. Accelerated Share Repurchase In May 2019, $50.0 $30.0 $20.0 May 7, 2019, $30.0 May 2019 January 2020, 0.6 $50.78 January 14, 2020. March 31, 2020, no

Note 15 - Income Taxes

Note 15 - Income Taxes	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Income Tax Disclosure [Text Block]	15. Income Taxes In response to the COVID- 19 March 2020. not The provision for income taxes was $1.6 three March 31, 2020, 21.4%. $1.5 three March 31, 2019, 24.6%. three March 31, 2020, 2019, $1.9 $2.0 first 2020. $0.4 three March 31, 2020 mpany recognized a net deferred tax liability of $11.2 3 . The Company files income tax returns in the United States on a federal basis, in certain U.S. states, and in Italy. The associated tax filings remain subject to examination by applicable tax authorities for a certain length of time following the tax year to which those filings relate. In connection with the preparation of the financial statements, the Company assesses whether it was more likely than not not not” not March 31, 2020 December 31, 2019.

Note 16 - Subsequent Event - Re

Note 16 - Subsequent Event - Revolving Credit Agreement	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Debt Disclosure [Text Block]	16. Subsequent Event - Revolving Credit Agreement As of March 31, 2020, no April 8, 2020, $50.0 2.08%. October 2022, may may The existing credit facility was entered into on October 24, 2017. five $50.0 may $50.0 $100.0 0.50%, one 1.0%, 0.25% 1.75% 0.25% five December 31, 2019 2018, no not first

Note 3 - Business Combinations

Note 3 - Business Combinations (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	Cash consideration $ 32,794 Deferred consideration 1,642 Estimated fair value of contingent consideration 40,700 Estimated total purchase consideration $ 75,136 Cash consideration $ 61,909 Estimated fair value of contingent consideration 28,376 Estimated total purchase consideration $ 90,285
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	Recognized identifiable assets acquired and liabilities assumed: Cash and cash equivalents $ 196 Accounts receivable 2,029 Inventories 9,088 Prepaid expenses and other current assets 364 Property and equipment, net 1,099 Right-of-use assets 944 Intangible assets 44,000 Accounts payable, accrued expenses and other current liabilities (2,763 ) Other long-term liabilities (594 ) Lease liabilities (735 ) Net assets acquired 53,628 Excess purchase price over fair value of net assets acquired 21,508 Estimated total purchase consideration $ 75,136 Recognized identifiable assets acquired and liabilities assumed: Cash and cash equivalents $ 1,072 Accounts receivable 5,368 Inventories 15,652 Prepaid expenses and other current assets 535 Property, plant and equipment 3,394 Other long-term assets 7,548 Intangible assets 48,900 Accounts payable, accrued expenses and other liabilities (3,929 ) Deferred tax liabilities (11,147 ) Net assets acquired 67,393 Excess purchase price over fair value of net assets acquired 22,892 Estimated total purchase consideration $ 90,285
Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]	Intangible assets acquired consist of: Developed Technology $ 41,100 Trade Name 1,800 Customer Relationships 1,100 Total Intangible Assets $ 44,000 Intangible assets acquired consist of: Developed Technology $ 37,000 Trade Name 3,400 Customer Relationships 7,900 IPR&D 600 Total Intangible Assets $ 48,900
Business Acquisition, Pro Forma Information [Table Text Block]	For the Three Months Ended March 31, 2020 2019 Total revenue $ 32,103 $ 27,934 Net income 5,510 3,105 Earnings per share: Basic $ 0.39 $ 0.22 Diluted 0.38 0.22 For the Three Months Ended March 31, 2020 2019 Total revenue $ 35,819 $ 31,494 Net income 1,601 22 Earnings per share: Basic $ 0.11 $ 0.00 Diluted 0.11 0.00

Note 4 - Fair Value Measureme_2

Note 4 - Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	Fair Value Measurements at Reporting Date Using Quoted Prices in Active Markets Significant Other Significant for Identical Assets Observable Inputs Unobservable Inputs March 31, 2020 (Level 1) (Level 2) (Level 3) Amortized Cost Cash equivalents: Bank Certificates of Deposit $ 250 $ - $ 250 $ - $ 250 Money Market Funds 51,682 51,682 51,682 Total Cash equivalents $ 51,932 $ 51,682 $ 250 $ - $ 51,932 Investments: Bank Certificates of Deposit $ 1,250 $ - $ 1,250 $ - $ 1,250 U.S. Treasury Bills 25,202 25,202 - - 25,027 Total Investments $ 26,452 $ 25,202 $ 1,250 $ - $ 26,277 Other current and long-term liabilities: Contingent Consideration - Short Term $ 4,303 $ - $ - $ 4,303 $ 4,303 Contingent Consideration - Long Term 40,251 - - 40,251 40,251 Total Other current and long-term liabilities $ 44,554 $ - $ - $ 44,554 $ 44,554 Fair Value Measurements at Reporting Date Using Quoted Prices in Active Markets Significant Other Significant for Identical Assets Observable Inputs Unobservable Inputs December 31, 2019 (Level 1) (Level 2) (Level 3) Amortized Cost Cash equivalents: Money Market Funds $ 48,971 $ 48,971 $ - $ - $ 48,971 Investments: U.S. Treasury Bills $ 27,480 $ 27,480 $ - $ - $ 27,479
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	March 31, 2020 Balance, beginning $ - Additions 69,076 Payments - Change in fair value (24,522 ) Balance, ending $ 44,554

Note 5 - Inventories (Tables)

Note 5 - Inventories (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Inventory, Current [Table Text Block]	March 31, December 31, 2020 2019 Raw materials $ 10,846 $ 12,058 Work-in-process 13,997 8,330 Finished goods 37,310 8,777 Total $ 62,153 $ 29,165 Inventories $ 35,081 $ 21,995 Other long-term assets 27,072 7,170

Note 6 - Intangible Assets (Tab

Note 6 - Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Finite-Lived and Indefinite-Lived Intangible Assets by Major Class [Table Text Block]	Three months ended March 31, 2020 Gross Less: Accumulated Less: Less: Net Book Weighted Developed technology $ 93,953 $ (2,986 ) $ (318 ) $ (9,958 ) $ 80,691 15 In-process research & development 5,006 (1,296 ) - - 3,710 Indefinite Customer relationships 9,000 - - (99 ) 8,901 10 Distributor relationships 4,700 (415 ) - (4,285 ) - 5 Patents 1,000 (182 ) - (543 ) 275 16 Tradenames 5,200 - - (59 ) 5,141 5 Total $ 118,859 $ (4,879 ) $ (318 ) $ (14,944 ) $ 98,718 13 December 31, 2019 Gross Less: Accumulated Less: Less: Net Book Weighted Developed technology $ 17,100 $ (2,934 ) $ (389 ) $ (9,657 ) $ 4,120 15 In-process research & development 4,406 (1,234 ) – – 3,172 Indefinite Distributor relationships 4,700 (415 ) – (4,285 ) – 5 Patents 1,000 (176 ) – (531 ) 293 16 Elevess tradename 1,000 – – (1,000 ) – 9 Total $ 28,206 $ (4,759 ) $ (389 ) $ (15,473 ) $ 7,585 11

Note 7 - Goodwill (Tables)

Note 7 - Goodwill (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Goodwill [Table Text Block]	Three Months Ended March 31, 2020 Twelve Months Ended December 31, 2019 Balance, beginning $ 7,694 $ 7,851 Effect of foreign currency adjustments (148 ) (157 ) Acquisitions 44,400 - Impairment loss (18,144 ) - Balance, ending $ 33,802 $ 7,694

Note 8 - Leases (Tables)

Note 8 - Leases (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Lease, Cost [Table Text Block]	For the three months ended March 31, 2020 March 31, 2019 Amortization of ROU Assets $ 37 $ - Interest on finance lease liabilities 7 - Finance lease expense $ 44 $ - Operating lease expense 574 522 Short-term lease expense - 2 Variable lease expense 63 52 Total lease expense $ 681 $ 576 For the three months ended March 31, 2020 March 31, 2019 Weighted Average Remaining Lease Term (in years) Operating leases 16.4 17.6 Financing leases 3.8 - Weighted Average Discount Rate Operating leases 4.1 % 4.1 % Financing leases 5.1 % - Other information Operating cash flows from operating leases $ 544 $ 497 Operating cash flows from financing leases $ 51 $ -
Lessee, Operating Lease and Finance Lease, Liability, Maturity [Table Text Block]	Years ended December 31, Operating Leases Financing Leases Total 2020 (Remaining 9 months) $ 1,793 $ 204 $ 1,997 2021 2,304 174 2,478 2022 2,240 166 2,406 2023 2,123 160 2,283 2024 2,059 44 2,103 Thereafter 21,374 - 21,374 Present value adjustment (8,681 ) (66 ) (8,630 ) Present value of lease payments 23,212 682 23,894 Less current portion included in accrued expenses and other current liabilities (1,481 ) (214 ) (1,695 ) Total lease liabilities $ 21,731 $ 468 $ 22,199

Note 9 - Accrued Expenses (Tabl

Note 9 - Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	March 31, December 31, Compensation and related expenses $ 2,707 $ 5,830 Professional fees 4,908 3,850 Operating lease liability - current 1,481 1,141 Clinical trial costs 1,528 788 Acquisition related contingent consideration 4,303 - Financing lease liability - current 214 - Other 1,141 836 Total $ 16,282 $ 12,445

Note 11 - Revenue (Tables)

Note 11 - Revenue (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Three Months Ended March 31, 2020 2019 Joint Pain Management $ 25,483 $ 22,850 Orthopedic Joint Preservation and Restoration 7,896 163 Other 2,018 1,704 $ 35,397 $ 24,717
Schedule of Revenue and Operating Income by Geographical Areas [Table Text Block]	Three Months Ended March 31, 2020 2019 Total Percentage of Total Percentage of Revenue Revenue Revenue Revenue Geographic Location: United States $ 26,306 74 % $ 20,089 81 % Europe 5,276 15 % 2,526 10 % Other 3,815 11 % 2,108 9 % Total $ 35,397 100 % $ 24,723 100 %

Note 12 - Equity Incentive Pl_2

Note 12 - Equity Incentive Plan (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Three Months Ended 2020 2019 Risk free interest rate 0.35% - 1.59% 2.44% - 2.54% Expected volatility 46.48% - 49.39% 44.34% - 44.41% Expected life (years) 4.0 3.5 Expected dividend yield 0.00% 0.00%
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended 2020 2019 Cost of product revenue $ 146 $ 92 Research & development 196 177 Selling, general & administrative (549 ) 1,117 Total stock-based compensation expense $ (207 ) $ 1,386
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	Three Months Ended 2020 2019 Grants: Stock options 210,775 104,292 RSUs 100,631 165,507 PSUs 57,400 114,500 Exercises: Stock options - 500 Forfeitures: Stock options 33,478 909 RSAs 8,574 3,333 RSUs 63,683 250 PSUs 63,000 - Expirations: Stock options 363 16,007

Note 13 - Earnings Per Share _2

Note 13 - Earnings Per Share ("EPS") (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended March 31, 2020 2019 Shares used in the calculation of basic earnings per share 14,202 14,185 Effect of dilutive securities: Stock options, RSAs, PSUs and RSUs 151 129 Diluted shares used in the calculation of earnings per share 14,353 14,314

Note 3 - Business Combination_2

Note 3 - Business Combinations (Details Textual) - USD ($) $ in Thousands	Feb. 03, 2020	Jan. 24, 2020	Mar. 31, 2020	Mar. 31, 2020	Dec. 31, 2019
Finite-Lived Intangible Asset, Useful Life (Year)				13 years	11 years
Developed Technology Rights [Member]
Finite-Lived Intangible Asset, Useful Life (Year)				15 years	15 years
Customer Relationships [Member]
Finite-Lived Intangible Asset, Useful Life (Year)				10 years
Trade Names [Member]
Finite-Lived Intangible Asset, Useful Life (Year)				5 years
Parcus Medical [Member]
Business Combination, Consideration Transferred, Total		$ 75,136
Payments to Acquire Businesses, Gross		32,794
Business Combination, Consideration Transferred, Deferred Consideration		1,642
Business Combination, Contingent Consideration, Liability, Total		40,700
Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High		60,000
Business Combination, Acquisition Related Costs		1,900
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total		44,000
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual			$ 2,600
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual			(900)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets, Total			$ 44,000	$ 44,000
Business Combination, Consideration Transferred, Liabilities Incurred		40,700
Parcus Medical [Member] | Developed Technology Rights [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total		$ 41,100
Finite-Lived Intangible Asset, Useful Life (Year)		15 years
Parcus Medical [Member] | Customer Relationships [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total		$ 1,100
Finite-Lived Intangible Asset, Useful Life (Year)		10 years
Parcus Medical [Member] | Trade Names [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total		$ 1,800
Finite-Lived Intangible Asset, Useful Life (Year)		5 years
Arthrosurface [Member]
Business Combination, Consideration Transferred, Total	$ 90,285
Payments to Acquire Businesses, Gross	61,909
Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High	40,000
Business Combination, Acquisition Related Costs	2,200
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total	48,900
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual				4,200
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual				$ (4,000)
Business Combination, Consideration Transferred, Liabilities Incurred	28,376
Business Combination, Consideration Transferred, Final Settlement Amount Recorded in Accounts Payable	400
Arthrosurface [Member] | Developed Technology Rights [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total	$ 37,000
Finite-Lived Intangible Asset, Useful Life (Year)	15 years
Arthrosurface [Member] | Customer Relationships [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total	$ 7,900
Finite-Lived Intangible Asset, Useful Life (Year)	10 years
Arthrosurface [Member] | Trade Names [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total	$ 3,400
Finite-Lived Intangible Asset, Useful Life (Year)	5 years
Arthrosurface [Member] | In Process Research and Development [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total	$ 600

Note 3 - Business Combination_3

Note 3 - Business Combinations - Consideration Transferred (Details) - USD ($) $ in Thousands	Feb. 03, 2020	Jan. 24, 2020
Parcus Medical [Member]
Cash consideration		$ 32,794
Deferred consideration		1,642
Estimated fair value of contingent consideration		40,700
Estimated total purchase consideration		$ 75,136
Arthrosurface [Member]
Cash consideration	$ 61,909
Estimated fair value of contingent consideration	28,376
Estimated total purchase consideration	$ 90,285

Note 3 - Business Combination_4

Note 3 - Business Combinations - Fair Value of Net Assets Acquired (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Feb. 03, 2020	Jan. 24, 2020	Dec. 31, 2019	Mar. 31, 2019	Dec. 31, 2018
Excess purchase price over fair value of net assets acquired	$ 33,802			$ 7,694	$ 7,694	$ 7,851
Parcus Medical [Member]
Cash and cash equivalents			$ 196
Accounts receivable			2,029
Inventories			9,088
Prepaid expenses and other current assets			364
Property and equipment, net			1,099
Right-of-use assets			944
Intangible assets			44,000
Accounts payable, accrued expenses and other current liabilities			(2,763)
Other long-term liabilities			(594)
Lease liabilities			(735)
Net assets acquired			53,628
Excess purchase price over fair value of net assets acquired			21,508
Estimated total purchase consideration			$ 75,136
Arthrosurface [Member]
Cash and cash equivalents		$ 1,072
Accounts receivable		5,368
Inventories		15,652
Prepaid expenses and other current assets		535
Property and equipment, net		3,394
Intangible assets		48,900
Accounts payable, accrued expenses and other current liabilities		(3,929)
Net assets acquired		67,393
Excess purchase price over fair value of net assets acquired		22,892
Estimated total purchase consideration		90,285
Other long-term assets		7,548
Deferred tax liabilities		$ (11,147)

Note 3 - Business Combination_5

Note 3 - Business Combinations - Intangible Assets Acquired (Details) - USD ($) $ in Millions	Feb. 03, 2020	Jan. 24, 2020
Parcus Medical [Member]
Intangible assets		$ 44
Arthrosurface [Member]
Intangible assets	$ 48.9
Developed Technology Rights [Member] | Parcus Medical [Member]
Intangible assets		41.1
Developed Technology Rights [Member] | Arthrosurface [Member]
Intangible assets	37
Trade Names [Member] | Parcus Medical [Member]
Intangible assets		1.8
Trade Names [Member] | Arthrosurface [Member]
Intangible assets	3.4
Customer Relationships [Member] | Parcus Medical [Member]
Intangible assets		$ 1.1
Customer Relationships [Member] | Arthrosurface [Member]
Intangible assets	7.9
In Process Research and Development [Member] | Arthrosurface [Member]
Intangible assets	$ 0.6

Note 3 - Business Combination_6

Note 3 - Business Combinations - Pro Forma Information (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Parcus Medical [Member]
Total revenue	$ 32,103	$ 27,934
Net income	$ 5,510	$ 3,105
Basic (in dollars per share)	$ 0.39	$ 0.22
Diluted (in dollars per share)	$ 0.38	$ 0.22
Arthrosurface [Member]
Total revenue	$ 35,819	$ 31,494
Net income	$ 1,601	$ 22
Basic (in dollars per share)	$ 0.11	$ 0
Diluted (in dollars per share)	$ 0.11	$ 0

Note 4 - Fair Value Measureme_3

Note 4 - Fair Value Measurements (Details Textual) $ in Thousands	Feb. 03, 2020USD ($)	Jan. 24, 2020USD ($)	Mar. 31, 2020USD ($)	Mar. 31, 2019USD ($)	Dec. 31, 2019USD ($)
Certificates of Deposit, at Carrying Value			$ 1,300
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability			(24,522)
COVID-19 Pandemic [Member]
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability			(24,500)
Parcus Medical and Arthrosurface Acquisitions [Member]
Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High			$ 100,000
Arthrosurface [Member]
Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High	$ 40,000
Arthrosurface [Member] | Measurement Input, Discount Rate [Member] | Regulatory Earn Out Milestone [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input			0.061
Arthrosurface [Member] | Probability of Achievement [Member] | Regulatory Earn Out Milestone [Member] | Minimum [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input			0.6
Arthrosurface [Member] | Probability of Achievement [Member] | Regulatory Earn Out Milestone [Member] | Maximum [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input			0.9
Arthrosurface [Member] | Measurement Input, Weighted Average Cost of Capital [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input			0.135		0.115
Parcus Medical [Member]
Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High		$ 60,000
Parcus Medical [Member] | Measurement Input, Weighted Average Cost of Capital [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input			0.16		0.145
US Treasury Bill Securities [Member]
Debt Securities, Available-for-sale, Total			$ 25,200		$ 27,500

Note 4 - Fair Value Measureme_4

Note 4 - Fair Value Measurements - Fair Value of Financial Instruments (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Contingent Consideration - Short Term	$ 4,303
Contingent Consideration - Long Term	40,251
Estimate of Fair Value Measurement [Member]
Cash equivalents	51,932
Investments	26,452
Contingent Consideration - Short Term	4,303
Contingent Consideration - Long Term	40,251
Business Combination, Contingent Consideration, Liability, Total	44,554
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member]
Cash equivalents	51,682
Investments	25,202
Contingent Consideration - Short Term
Contingent Consideration - Long Term
Business Combination, Contingent Consideration, Liability, Total
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member]
Cash equivalents	250
Investments	1,250
Contingent Consideration - Short Term
Contingent Consideration - Long Term
Business Combination, Contingent Consideration, Liability, Total
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member]
Cash equivalents
Investments
Contingent Consideration - Short Term	4,303
Contingent Consideration - Long Term	40,251
Business Combination, Contingent Consideration, Liability, Total	44,554
Estimate of Fair Value Measurement [Member] | Certificates of Deposit [Member]
Cash equivalents	250
Investments	1,250
Estimate of Fair Value Measurement [Member] | Certificates of Deposit [Member] | Fair Value, Inputs, Level 1 [Member]
Cash equivalents
Investments
Estimate of Fair Value Measurement [Member] | Certificates of Deposit [Member] | Fair Value, Inputs, Level 2 [Member]
Cash equivalents	250
Investments	1,250
Estimate of Fair Value Measurement [Member] | Certificates of Deposit [Member] | Fair Value, Inputs, Level 3 [Member]
Cash equivalents
Investments
Estimate of Fair Value Measurement [Member] | Money Market Funds [Member]
Cash equivalents	51,682	48,971
Estimate of Fair Value Measurement [Member] | Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Cash equivalents	51,682	48,971
Estimate of Fair Value Measurement [Member] | Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]
Cash equivalents
Estimate of Fair Value Measurement [Member] | Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]
Cash equivalents
Estimate of Fair Value Measurement [Member] | US Treasury Securities [Member]
Investments	25,202	27,480
Estimate of Fair Value Measurement [Member] | US Treasury Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Investments	25,202	27,480
Estimate of Fair Value Measurement [Member] | US Treasury Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Investments
Estimate of Fair Value Measurement [Member] | US Treasury Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Investments
Reported Value Measurement [Member]
Cash equivalents	51,932
Investments	26,277
Contingent Consideration - Short Term	4,303
Contingent Consideration - Long Term	40,251
Business Combination, Contingent Consideration, Liability, Total	44,554
Reported Value Measurement [Member] | Certificates of Deposit [Member]
Cash equivalents	250
Investments	1,250
Reported Value Measurement [Member] | Money Market Funds [Member]
Cash equivalents	51,682
Reported Value Measurement [Member] | Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]
Cash equivalents		48,971
Reported Value Measurement [Member] | US Treasury Securities [Member]
Investments	$ 25,027
Reported Value Measurement [Member] | US Treasury Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Investments		$ 27,479

Note 4 - Fair Value Measureme_5

Note 4 - Fair Value Measurements - Contingent Consideration (Details) - Contingent Consideration [Member] $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)
Balance, beginning
Additions	69,076
Payments
Change in fair value	(24,522)
Balance, ending	$ 44,554

Note 5 - Inventories (Details T

Note 5 - Inventories (Details Textual) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Inventory, Net, Total	$ 35,081	$ 21,995
Inventory Acquired from Acquisition [Member]
Inventory, Net, Total	$ 24,700

Note 5 - Inventories - Summary

Note 5 - Inventories - Summary of Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Raw materials	$ 10,846	$ 12,058
Work-in-process	13,997	8,330
Finished goods	37,310	8,777
Total	62,153	29,165
Inventories, net	35,081	21,995
Other long-term assets	$ 27,072	$ 7,170

Note 6 - Intangible Assets (Det

Note 6 - Intangible Assets (Details Textual) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Amortization of Intangible Assets, Total	$ 1,300	$ 300
Impairment of Intangible Assets, Finite-lived	318	$ 281	$ 389
Asset Impairment Charges, Total	0
Parcus Medical and Arthrosurface [Member]
Finite-lived Intangible Assets Acquired	92,900
Parcus Medical and Arthrosurface [Member] | Selling, General and Administrative Expenses [Member]
Impairment of Intangible Assets, Finite-lived	$ 300

Note 6 - Intangible Assets - Su

Note 6 - Intangible Assets - Summary of Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Gross Value	$ 118,859		$ 28,206
Accumulated Currency Translation Adjustment	(4,879)		(4,759)
Impairment	(318)	$ (281)	(389)
Accumulated Amortization	(14,944)		(15,473)
Intangible assets, net	$ 98,718		$ 7,585
Useful life (Year)	13 years		11 years
In Process Research and Development [Member]
Gross Value	$ 5,006		$ 4,406
Accumulated Currency Translation Adjustment	(1,296)		(1,234)
Impairment
Accumulated Amortization
Intangible assets, net	3,710		3,172
Developed Technology Rights [Member]
Gross Value	93,953		17,100
Accumulated Currency Translation Adjustment	(2,986)		(2,934)
Impairment	(318)		(389)
Accumulated Amortization	(9,958)		(9,657)
Intangible assets, net	$ 80,691		$ 4,120
Useful life (Year)	15 years		15 years
Customer Relationships [Member]
Gross Value	$ 9,000
Accumulated Currency Translation Adjustment
Impairment
Accumulated Amortization	(99)
Intangible assets, net	$ 8,901
Useful life (Year)	10 years
Distribution Rights [Member]
Gross Value	$ 4,700		$ 4,700
Accumulated Currency Translation Adjustment	(415)		(415)
Impairment
Accumulated Amortization	(4,285)		(4,285)
Intangible assets, net
Useful life (Year)	5 years		5 years
Patents [Member]
Gross Value	$ 1,000		$ 1,000
Accumulated Currency Translation Adjustment	(182)		(176)
Impairment
Accumulated Amortization	(543)		(531)
Intangible assets, net	$ 275		$ 293
Useful life (Year)	16 years		16 years
Elevess Trade Name [Member]
Gross Value			$ 1,000
Accumulated Currency Translation Adjustment
Impairment
Accumulated Amortization			(1,000)
Intangible assets, net
Useful life (Year)			9 years
Trade Names [Member]
Gross Value	$ 5,200
Accumulated Currency Translation Adjustment
Impairment
Accumulated Amortization	(59)
Intangible assets, net	$ 5,141
Useful life (Year)	5 years

Note 7 - Goodwill (Details Text

Note 7 - Goodwill (Details Textual)	3 Months Ended
	Mar. 31, 2020
Number of Reporting Units	2

Note 7 - Goodwill - Changes in

Note 7 - Goodwill - Changes in the Carrying Value of Goodwill (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Balance	$ 7,694	$ 7,851
Effect of foreign currency adjustments	(148)	(157)
Acquisitions	44,400
Impairment loss	(18,144)
Balance	$ 33,802	$ 7,694

Note 8 - Leases - Lease Expense

Note 8 - Leases - Lease Expense and Other Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Amortization of ROU Assets	$ 37
Interest on finance lease liabilities	7
Finance lease expense	44
Operating lease expense	574	522
Short-term lease expense		2
Variable lease expense	63	52
Total lease expense	$ 681	$ 576
Operating leases (Year)	16 years 146 days	17 years 219 days
Financing leases (Year)	3 years 292 days
Operating leases	4.10%	4.10%
Financing leases	5.10%
Right-of-use assets obtained in exchange for operating lease liabilities as of January 1, 2019	$ 544	$ 497
Operating cash flows from financing leases	$ 51

Note 8 - Leases - Future Minimu

Note 8 - Leases - Future Minimum Rental Payments for Operating Leases (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
2020 (Remaining 9 months), operating leases	$ 1,793
2020 (Remaining 9 months), financing leases	204
2020 (Remaining 9 months)	1,997
2021, operating leases	2,304
2021, financing leases	174
2021	2,478
2022, operating leases	2,240
2022, financing leases	166
2022	2,406
2023, operating leases	2,123
2023, financing leases	160
2023	2,283
2024, operating leases	2,059
2024, financing leases	44
2024	2,103
Thereafter, operating leases	21,374
Thereafter, financing leases
Thereafter	21,374
Present value adjustment, operating leases	(8,681)
Present value adjustment, financing leases	(66)
Present value adjustment	(8,630)
Less current portion included in Accrued expenses and other current liabilities, operating leases	(1,481)	$ (1,141)
Less current portion included in Accrued expenses and other current liabilities, financing leases	(214)
Total lease liabilities, operating leases	21,731	$ 21,367
Total lease liabilities, financing leases	468
Total lease liabilities	22,199
Liabilities [Member]
Present value of lease payments, operating leases	23,212
Present value of lease payments, financing leases	682
Present value of lease payments	23,894
Accrued Expenses and Other Current Liabilities [Member]
Less current portion included in Accrued expenses and other current liabilities, operating leases	(1,481)
Less current portion included in Accrued expenses and other current liabilities, financing leases	(214)
Less current portion included in accrued expenses and other current liabilities	$ (1,695)

Note 9 - Accrued Expenses - Sum

Note 9 - Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Compensation and related expenses	$ 2,707	$ 5,830
Professional fees	4,908	3,850
Operating lease liability - current	1,481	1,141
Clinical trial costs	1,528	788
Acquisition related contingent consideration	4,303
Financing lease liability - current	214
Other	1,141	836
Total	$ 16,282	$ 12,445

Note 10 - Commitments and Con_2

Note 10 - Commitments and Contingencies (Details Textual) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Standard and Extended Product Warranty Accrual, Ending Balance	$ 0	$ 0

Note 11 - Revenue (Details Text

Note 11 - Revenue (Details Textual) $ in Millions	3 Months Ended
	Mar. 31, 2020USD ($)
Contract with Customer, Liability, Total	$ 0.1
Mitek [Member]
Revenues From Agreements as Percent of Total Revenue	54.00%

Note 11 - Revenue - Product Rev

Note 11 - Revenue - Product Revenue by Product Group (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenue	$ 35,397	$ 24,723
Joint Pain Management Therapies [Member]
Revenue	25,483	22,850
Orthopedic Joint Preservation and Restoration Care [Member]
Revenue	7,896	163
Manufactured Product, Other [Member]
Revenue	2,018	1,704
Product [Member]
Revenue	$ 35,397	$ 24,717

Note 11 - Revenue - Total Reven

Note 11 - Revenue - Total Revenue by Geographic Location (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenue	$ 35,397	$ 24,723
Percentage of Revenue	100.00%	100.00%
UNITED STATES
Revenue	$ 26,306	$ 20,089
Percentage of Revenue	74.00%	81.00%
Europe [Member]
Revenue	$ 5,276	$ 2,526
Percentage of Revenue	15.00%	10.00%
Other Location [Member]
Revenue	$ 3,815	$ 2,108
Percentage of Revenue	11.00%	9.00%

Note 12 - Equity Incentive Pl_3

Note 12 - Equity Incentive Plan (Details Textual) - USD ($) $ in Thousands	Jan. 29, 2020	Mar. 31, 2020	Mar. 31, 2019
Share-based Compensation, One-time Benefit for Unexpected Death of Former President	$ 1,800
Share-based Payment Arrangement, Expense		$ (207)	$ 1,386
Stock Options, PSUs and RSUs to Employees and RSUs to Non-employee Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)		3 years
Performance Shares [Member]
Performance Conditions, Business Target, Percentage of Performance Conditions Based on Achievement in Current Fiscal Year		40.00%
Performance Conditions, Financial Target, Percentage of Performance Conditions Based on Company’s Operating Results in next Fiscal Year		60.00%
Share-based Payment Arrangement, Expense		$ 500

Note 12 - Equity Incentive Pl_4

Note 12 - Equity Incentive Plan - Assumptions Used to Estimate Fair Value of Stock Options and Stock Appreciation Rights (Details)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Expected volatility
Expected life (years) (Year)	4 years	3 years 182 days
Expected dividend yield	0.00%	0.00%
Minimum [Member]
Risk free interest rate	0.35%	2.44%
Expected volatility	46.48%	44.34%
Maximum [Member]
Risk free interest rate	1.59%	2.54%
Expected volatility	49.39%	44.41%

Note 12 - Equity Incentive Pl_5

Note 12 - Equity Incentive Plan - Total Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Stock-based compensation expense	$ (207)	$ 1,386
Cost of Sales [Member]
Stock-based compensation expense	146	92
Research and Development Expense [Member]
Stock-based compensation expense	196	177
Selling, General and Administrative Expenses [Member]
Stock-based compensation expense	$ (549)	$ 1,117

Note 12 - Equity Incentive Pl_6

Note 12 - Equity Incentive Plan - Granted and Exercised Stock-based Compensation Awards (Details) - shares	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Share-based Payment Arrangement, Option [Member]
Grants (in shares)	210,775	104,292
Exercises (in shares)		500
Forfeitures (in shares)	33,478	909
Expirations (in shares)	363	16,007
Restricted Stock Units (RSUs) [Member]
Grants (in shares)	100,631	165,507
Forfeitures (in shares)	63,683	250
Performance Restricted Stock Units [Member]
Grants (in shares)	57,400	114,500
Forfeitures (in shares)	63,000
Restricted Stock [Member]
Forfeitures (in shares)	8,574	3,333

Note 13 - Earnings Per Share _3

Note 13 - Earnings Per Share ("EPS") (Details Textual) - shares shares in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Share-based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	0.6	1

Note 13 - Earnings Per Share _4

Note 13 - Earnings Per Share ("EPS") - Basic and Diluted Earnings Per Share (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Basic weighted average common shares outstanding (in shares)	14,202	14,185
Stock options, RSAs, PSUs and RSUs (in shares)	151	129
Diluted shares used in the calculation of earnings per share (in shares)	14,353	14,314

Note 14 - Accelerated Share R_2

Note 14 - Accelerated Share Repurchases (Details Textual) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	Jan. 17, 2020	May 07, 2019	May 02, 2019
Stock Repurchase Program, Authorized Amount			$ 50
Accelerated Stock Repurchase [Member]
Stock Repurchase Program, Authorized Amount		$ 30	30
Accelerated Stock Repurchase [Member] | Morgan Stanley & Co., LLC [Member]
Stock Repurchased and Retired During Period, Shares (in shares)	0.6
Accelerated Share Repurchases, Final Price Paid Per Share (in dollars per share)	$ 50.78
Repurchase from Open Market [Member]
Stock Repurchase Program, Authorized Amount			$ 20

Note 15 - Income Taxes (Details

Note 15 - Income Taxes (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Income Tax Expense (Benefit), Total	$ 1,580	$ 1,473
Effective Income Tax Rate Reconciliation, Percent, Total	21.40%	24.60%
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount	$ 1,900
Effective Income Tax Rate Reconciliation,Change in Fair Value of Business Acquisition Contingent Consideration Liabilities, Amount	(2,000)
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount	400
Deferred Income Tax Liabilities, Net, Total	16,030		$ 4,331
Deferred Tax Assets, Valuation Allowance, Total	$ 0		$ 0

Note 16 - Subsequent Event - _2

Note 16 - Subsequent Event - Revolving Credit Agreement (Details Textual) - Revolving Credit Facility [Member] - USD ($) $ in Thousands	Oct. 24, 2017	Jun. 30, 2020	Dec. 31, 2019	Dec. 31, 2018
Debt Instrument, Term (Year)	5 years
Line of Credit Facility, Current Borrowing Capacity	$ 50,000
Line of Credit Facility, Additional Borrowing Capacity	50,000
Line of Credit Facility, Maximum Borrowing Capacity	$ 100,000
Line of Credit Facility, Commitment Fee Percentage	0.25%
Long-term Line of Credit, Total			$ 0	$ 0
Minimum [Member]
Debt Instrument, Basis Spread on Variable Rate	0.25%
Maximum [Member]
Debt Instrument, Basis Spread on Variable Rate	1.75%
Fed Funds Effective Rate Overnight Index Swap Rate [Member]
Debt Instrument, Basis Spread on Variable Rate	0.50%
London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate	1.00%
Forecast [Member]
Proceeds from Long-term Lines of Credit		$ 50,000
Debt Instrument, Interest Rate, Stated Percentage		2.08%